Recall of Lots of Nitroglycerin Injection

recall alert
Image Credit: NLIPW

The National Agency for Food and Drug Administration and Control (NAFDAC) is alerting the public that the Singapore Health Science Authority (HSA) has issued a recall of all unexpired lots of Nitroglycerin injection manufactured by Advanced Pharma, Inc. doing business as Avella of Houston, USA.

The recall issued on June 29, 2017, was due to a laboratory test result which indicated a lower than expected potency on certain lots of compounded Nitroglycerin injection which may lead to a lower dose being administered. The result, serious health complications.

Nitroglycerine is used to control high blood pressure, congestive heart failure, lung congestion and chest pain especially in heart attack patients. It decreases the workload on the heart by enlarging (dilating) blood vessels

PRODUCT DETAILS

Product Name:                        Nitoglycerin Injection

Lot Number:                            All unexpired lots

Manufacturing Dates:            March 3, and May 31, 2017

Manufacturer:                         Advanced Pharma, Inc. doing business as Avella of Houston USA.

Healthcare Provider Action

  • Healthcare providers in possession of these affected products should stop using them and return unused portions to the nearest NAFDAC office.
  • Report adverse events relating to use of these medicines to NAFDAC PRASCOR (20543-Toll free from all networks) or via pharmacovigilance@nafdac.gov.ng
Print Friendly, PDF & Email
FILE A TRADEMARK
About Bob Aroture 564 Articles
Bob is a Senior Editor and Content Development Manager at Nigerian Law Intellectual Property Watch. He holds a BS degree, with a major in biochemistry. He works directly with the Newsroom Team. His focus areas are technology and innovation, and pharmaceutical technology. Email: editorial@nlipw.com